Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FUJRF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,892.90 on August 11, 2025, for the supply of Nucala 100 mg/ml auto-injectors. The contract, which is set to be completed by August 12, 2025, utilizes a firm fixed-price structure and was funded by the Defense Logistics Agency (DLA), the Department of Defense's logistics and supply chain management organization. This delivery order represents a firm fixed-price purchase under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a significant $499.999 billion vehicle valid through November 2026 that enables DLA to procure a comprehensive range of pharmaceutical products and medical supplies for military health facilities worldwide.
The award carries no specific set-aside designation, reflecting DMS Pharmaceutical Group's competitive strength as an established woman-owned small business in federal pharmaceutical procurement. The contractor's Park Ridge, Illinois location serves as the place of performance for this delivery order. Nucala (mepolizumab) is a biologic medication used in respiratory and immunological treatments, and its inclusion in DLA's pharmaceutical supply portfolio supports the medical readiness and healthcare delivery capabilities of Department of Defense facilities globally. This contract exemplifies DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, providing direct distribution of specialized medications and biologics to military medical facilities.
Quick answers
Who was awarded contract SPE2DB25FUJRF?
SPE2DB25FUJRF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 11, 2025.
How much is contract SPE2DB25FUJRF worth?
The government has obligated $1,893 on SPE2DB25FUJRF.
Is contract SPE2DB25FUJRF an order under another contract?
Yes. SPE2DB25FUJRF is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJRF competed?
The extent of competition for SPE2DB25FUJRF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award